keyword
MENU ▼
Read by QxMD icon Read
search

golimumab

keyword
https://www.readbyqxmd.com/read/28094756/treatment-modifying-factors-of-biologics-for-psoriatic-arthritis-a-systematic-review-and-bayesian-meta-regression
#1
REVIEW
Eric Druyts, Jacqueline B Palmer, Chakrapani Balijepalli, Keith Chan, Mir Sohail Fazeli, Vivian Herrera, Jeroen P Jansen, Jay J H Park, Steve Kanters, Andreas Reimold
OBJECTIVES: The aim of this study was to explore factors that modify treatment effects of non-conventional biologics versus placebo in patients with psoriatic arthritis. METHODS: A systematic literature review and meta-regression was conducted. The biologics included etanercept, infliximab, adalimumab, golimumab, certolizumab, ustekinumab, tocilizumab, anakinra, abatacept, rituximab, and secukinumab. Outcomes included American College of Rheumatology (ACR) 20 and 50, Psoriasis Area Severity Index (PASI) 75, and 36-Item Short Form Health Survey (SF-36) Physical and Mental Component Summaries (PCS and MCS)...
January 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28078646/mucosal-healing-in-ulcerative-colitis-a-comprehensive-review
#2
REVIEW
Pedro Boal Carvalho, José Cotter
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by periods of remission and periods of relapse. Patients often present with symptoms such as rectal bleeding, diarrhea and weight loss, and may require hospitalization and even colectomy. Long-term complications of UC include decreased quality of life and productivity and an increased risk of colorectal cancer. Mucosal healing (MH) has gained progressive importance in the management of UC patients. In this article, we review the endoscopic findings that define both mucosal injury and MH, and the strengths and limitations of the scoring systems currently available in clinical practice...
January 11, 2017: Drugs
https://www.readbyqxmd.com/read/28058024/short-term-effectiveness-of-golimumab-for-ulcerative-colitis-observational-multicenter-study
#3
Marta Maia Bosca-Watts, Xavier Cortes, Marisa Iborra, Jose Maria Huguet, Laura Sempere, Gloria Garcia, Rafa Gil, MariFe Garcia, Marga Muñoz, Pedro Almela, Nuria Maroto, Jose Maria Paredes
AIM: To evaluate the real-world effectiveness of golimumab in ulcerative colitis (UC) and to identify predictors of response. METHODS: We conducted an observational, prospective and multi-center study in UC patients treated with golimumab, from September 2014 to September 2015. Clinical activity was assessed at week 0 and 14 with the physician's global clinical assessment (PGA) and the partial Mayo score. Colonoscopies and blood tests were performed, following daily-practice clinical criteria, and the results were recorded in an SPSS database...
December 21, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28035867/clinical-response-to-golimumab-in-rheumatoid-arthritis-patients-who-were-receiving-etanercept-or-adalimumab-results-of-a-multicenter-active-treatment-study
#4
Joseph E Huffstutter, Shelly Kafka, Lawrence H Brent, Marco Matucci-Cerinic, Kezhen L Tang, Marc Chevrier, Trev Sprabery, Raphael J DeHoratius
OBJECTIVE: Evaluate the efficacy and safety of subcutaneous (SC) golimumab+methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite etanercept+MTX or adalimumab+MTX therapy and evaluate whether intravenous (IV) golimumab could rescue patients who were nonresponders to SC golimumab. METHODS: In this multicenter, assessor-blinded, active-switch study of RA patients (n = 433) with inadequate response to etanercept or adalimumab +MTX, patients continued MTX and received open-label SC golimumab 50mg q4weeks through week12...
December 30, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28031053/serum-biomarkers-and-changes-in-clinical-mri-evidence-of-golimumab-treated-patients-with-ankylosing-spondylitis-results-of-the-randomized-placebo-controlled-go-raise-study
#5
Robert D Inman, Xenofon Baraliakos, Kay-Geert A Hermann, Jürgen Braun, Atul Deodhar, Désirée van der Heijde, Stephen Xu, Benjamin Hsu
BACKGROUND: In the present study, we evaluated relationships between serum biomarkers and clinical/magnetic resonance imaging (MRI) findings in golimumab-treated patients with ankylosing spondylitis. METHODS: In the GO-RAISE study, 356 patients with ankylosing spondylitis randomly received either placebo (n = 78) or golimumab 50 mg or 100 mg (n = 278) injections every 4 weeks through week 24 (placebo-controlled); patients continuing GO-RAISE received golimumab through week 252...
December 28, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28025727/efficacy-of-switching-from-infliximab-to-subcutaneous-golimumab-in-patients-with-rheumatoid-arthritis-to-control-disease-activity-or-adverse-events
#6
Hiroki Wakabayashi, Hitoshi Inada, Yosuke Nishioka, Masahiro Hasegawa, Kusuki Nishioka, Akihiro Sudo
BACKGROUND: Some rheumatoid arthritis (RA) patients initially respond to treatment with infliximab (IFX), but subsequently their responsiveness decreases. OBJECTIVES: Our objective was to evaluate the efficacy and safety of switching from IFX to subcutaneous golimumab (GLM-SC) in RA patients. METHODS: Thirty-three patients who had been treated for a mean 4.4 years with IFX (3-6 mg/kg/8 weeks) were switched to GLM-SC to control disease activity or adverse events...
December 26, 2016: Drugs in R&D
https://www.readbyqxmd.com/read/28013201/risk-of-serious-adverse-effects-of-biological-and-targeted-drugs-in-patients-with-rheumatoid-arthritis-a-systematic-review-meta-analysis
#7
Simon Tarp, Daniel Eric Furst, Maarten Boers, George Luta, Henning Bliddal, Ulrik Tarp, Karsten Heller Asmussen, Birgitte Brock, Anna Dossing, Tanja Schjødt Jørgensen, Steffen Thirstrup, Robin Christensen
OBJECTIVES: To determine possible differences in serious adverse effects among the 10 currently approved biological and targeted synthetic DMARDs (b/ts-DMARDs) for RA. METHODS: Systematic review in bibliographic databases, trial registries and websites of regulatory agencies identified randomized trials of approved b/ts-DMARDs for RA. Network meta-analyses using mixed-effects Poisson regression models were conducted to calculate rate ratios for serious adverse events (SAEs) and deaths between each of the 10 drugs and control (i...
December 24, 2016: Rheumatology
https://www.readbyqxmd.com/read/28011850/sarcoidosis-neurotoxoplasmosis-and-golimumab-therapy
#8
D P Misra, K G Chengappa, A Mahadevan, V K Jain, V S Negi
No abstract text is available yet for this article.
December 2016: QJM: Monthly Journal of the Association of Physicians
https://www.readbyqxmd.com/read/28010883/effectiveness-and-drug-survival-of-tnf-inhibitors-in-the-treatment-of-psoriatic-arthritis-a-prospective-cohort-study
#9
Kalle Aaltonen, Arto Heinonen, Jaana Joensuu, Pinja Parmanne, Anna Karjalainen, Tuire Varjolahti-Lehtinen, Toini Uutela, Maija Puurtinen-Vilkki, Leena Arstila, Marja Blom, Tuulikki Sokka, Dan Nordström
BACKGROUND AND OBJECTIVES: Tumor necrosis factor (TNF)-inhibitors are used to treat psoriatic arthritis (PsA), but only a limited number of observational studies on this subject have been published thus far. The aim of this research was to analyze the effectiveness and drug survival of TNF-inhibitors in the treatment of PsA. METHODS: PsA patients identified from the National Register for Biologic Treatment in Finland (ROB-FIN) starting their first, second, or third TNF-inhibitor treatment between 2004 and 2014 were included...
September 16, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28010149/outcomes-of-tumor-necrosis-factor-inhibitor-cycling-versus-switching-to-a-disease-modifying-anti-rheumatic-drug-with-a-new-mechanism-of-action-among-patients-with-rheumatoid-arthritis
#10
Benjamin Chastek, Laura K Becker, Chieh-I Chen, Puneet Mahajan, Jeffrey R Curtis
OBJECTIVES: To examine treatment patterns, treatment effectiveness, and treatment costs for 1 year after patients with rheumatoid arthritis switched from a tumor necrosis factor inhibitor (TNFi) (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab), either cycling to another TNFi ("TNFi cyclers") or switching to a new mechanism of action (abatacept, tocilizumab, or tofacitinib) ("new MOA switchers"). METHODS: This retrospective cohort study used administrative claims data for a national insurer...
January 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/27974105/anti-tnf-treatment-response-in-rheumatoid-arthritis-patients-with-moderate-disease-activity-a-prospective-observational-multicentre-study-moderate
#11
Fulvia Ceccarelli, Umberto Massafra, Carlo Perricone, Luca Idolazzi, Roberto Giacomelli, Rosella Tirri, Romualdo Russo, Giovanni Pistone, Piero Ruscitti, Simone Parisi, Pier Paolo Sainaghi, Fabio Cacciapaglia, Alessandro Zullo, Valentina Marino, Alberto Migliore, Guido Valesini
OBJECTIVES: Rheumatoid arthritis (RA) patients with moderate disease activity show progression of joint damage and have impaired quality of life, physical function, work and daily activities. Little is known about management of patients with moderate RA. The aim of the study was to assess the 1-year response to anti-TNF in biologic-naïve RA patients with moderate (3.2 <DAS28 ≤5.1) disease activity despite DMARD treatment, in the Italian clinical practice. METHODS: The MODERATE study is a multicentre prospective, cohort non-interventional study, conducted in 19 Italian rheumatology sites...
December 9, 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/27971748/treatment-persistence-with-golimumab-in-france
#12
M Belhassen, C Hudry, M Woronoff, L Levy Bachelot, C Deschamps, M Ginoux, E van Ganse, B Fautrel, F Tubach
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971419/real-world-quality-adjusted-life-years-gains-in-portuguese-patients-with-rheumatoid-arthritis-following-1-year-of-golimumab-treatment
#13
P A Laires, A F Mourão, C Ribeiro, J Borges, M J Gonçalves, J M Bernardes, S Fernandes, R Dezerto, M Eusébio, M J Santos, H Canhão
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27960557/the-biologics-of-ulcerative-colitis
#14
Fabio Salvatore Macaluso, Sara Renna, Ambrogio Orlando, Mario Cottone
Tumor necrosis factor α inhibitors dramatically changed the management of moderate-to-severe phenotypes of ulcerative colitis. The recent incoming of vedolizumab, which targets gut-specific leukocyte trafficking, provides a new biologic option for these patients. Areas covered: This review focuses on the rationale of use, efficacy, and safety profile of all biologics currently approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of ulcerative colitis, including tumor necrosis factor α inhibitors (Infliximab and biosimilars, adalimumab, and golimumab), and the more recent vedolizumab...
February 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/27942977/maintenance-of-efficacy-and-safety-with-subcutaneous-golimumab-in-rheumatoid-arthritis-patients-with-low-disease-activity-who-previously-received-tnf-inhibitors
#15
Hiroki Wakabayashi, Hitoshi Inada, Yosuke Nishioka, Masahiro Hasegawa, Akihiro Sudo, Kusuki Nishioka
The study was conducted to evaluate continued maintenance of the efficacy and safety of therapy by switching to subcutaneous golimumab (GLM-SC) in rheumatoid arthritis patients with low disease activity or remission who previously received a tumor necrosis factor (TNF) inhibitor. Thirty patients who had been treated with etanercept or infliximab were switched to GLM-SC in maintaining disease activity at a low level. The patients were divided into two groups through discussion with each patient, considering general condition and convenience: the low disease activity (LDA) group and the LDAq8w group, which included patients with low disease activity or remission who switched to 50 mg GLM therapy at 4- and 8-week intervals, respectively...
December 9, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27931158/drug-survival-on-tumour-necrosis-factor-inhibitors-in-patients-with-rheumatoid-arthritis-in-finland
#16
K J Aaltonen, J T Joensuu, L Pirilä, M Kauppi, T Uutela, T Varjolahti-Lehtinen, T Yli-Kerttula, P Isomäki, D Nordström, T Sokka
OBJECTIVE: A systematic review found that an average of 27% of rheumatoid arthritis (RA) patients using tumour necrosis factor (TNF) inhibitors discontinue their treatment within 1 year. The aim of this study was to assess drug survival on TNF inhibitors among patients with RA. METHODS: Patients were identified from the National Register for Biologic Treatment in Finland (ROB-FIN), which is a longitudinal cohort study established to monitor the effectiveness and safety of biologic drugs in rheumatic diseases...
December 8, 2016: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/27924644/risk-of-malignancies-using-anti-tnf-agents-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis-a-systematic-review-and-meta-analysis
#17
Stefanos Bonovas, Silvia Minozzi, Theodore Lytras, Marien González-Lorenzo, Valentina Pecoraro, Silvia Colombo, Ilaria Polloni, Lorenzo Moja, Michela Cinquini, Valentina Marino, Delia Goletti, Andrea Matucci, Giuliano Tocci, Giuseppe Maria Milano, Raffaele Scarpa, Fabrizio Cantini
Malignancies have been reported in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, treated with anti-tumour necrosis factor (anti-TNF) agents. Areas covered: We conducted a systematic review of randomized controlled trials (RCTs) to determine the effect of anti-TNF agents on the occurrence of cancer (any type). Literature databases were searched up to May 2014 to identify relevant studies that evaluated adalimumab, certolizumab, etanercept, golimumab, or infliximab, compared with placebo or no treatment...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27924643/risk-of-infections-using-anti-tnf-agents-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis-a-systematic-review-and-meta-analysis
#18
Silvia Minozzi, Stefanos Bonovas, Theodore Lytras, Valentina Pecoraro, Marien González-Lorenzo, Anan Judina Bastiampillai, Eugenia Maria Gabrielli, Andrea Carlo Lonati, Lorenzo Moja, Michela Cinquini, Valentina Marino, Andrea Matucci, Giuseppe Maria Milano, Giuliano Tocci, Raffaele Scarpa, Delia Goletti, Fabrizio Cantini
Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associated with an increased risk of infectious adverse events. Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infection)...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27920336/reasons-for-discontinuation-and-adverse-effects-of-tnf%C3%AE-inhibitors-in-a-cohort-of-patients-with-rheumatoid-arthritis-and-ankylosing-spondylitis
#19
María Henar García-Lagunar, María Rocío Gutiérrez-Cívicos, María Sergia García-Simón, Pablo Conesa-Zamora, Enrique Jimenez-Santos, Pedro Cano-Vivar, Andrés García-Márquez, Iris Muñoz-García, Alice Charlotte Viney
BACKGROUND: The introduction of anti-tumor necrosis factor α (anti-TNFα) drugs has improved the clinical outcomes in rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, these drugs may cause adverse effects that motivate a change in or discontinuation of the treatment. OBJECTIVE: To evaluate the causes of discontinuation or changes in the dosage regimen in a cohort of patients with RA and AS treated with infliximab, adalimumab, etanercept, and golimumab under clinical practice conditions...
December 5, 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/27919316/corrigendum-adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-not-previously-treated-with-disease-modifying-antirheumatic-drugs-and-after-the-failure-of-conventional-disease-modifying
#20
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young, Allan Wailoo
No abstract text is available yet for this article.
November 2016: Health Technology Assessment: HTA
keyword
keyword
19896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"